A Clinical Trial to Find the Optimal Dose of BNT323 and BNT327 for Advanced Breast Cancer
Phase 1/2
380
about 4.1 years
18+
9 sites in CA, FL, GA +5
About this study
This trial is testing a combination treatment, BNT323 and BNT327, in people with advanced breast cancer. The goal is to find the best dose of this combination and see if it's safe and helpful.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take BNT323
- 2.Take BNT327
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Occurrence of Treatment-emergent adverse events (TEAEs), Grade ≥3 TEAEs, serious adverse events (SAEs), treatment-related TEAEs, treatment-related Grade ≥3 TEAEs, and treatment-related SAEs, Occurrence of dose interruption, reduction, and discontinuation due to TEAEs, Part 2 - Objective response rate (ORR)
Secondary: Part 1 - ORR, Part 2 - Disease control rate (DCR), Part 2 - Duration of response (DoR), Part 2 Cohort 1 only - Progression free survival (PFS)
Oncology